Repros Therapeutics

Repros Therapeutics — Investor Presentation (January 2008)

40 slides from Repros Therapeutics's investor presentation, Jan 10, 2008

  1. Slide 1: Developing clinical stage small molecule therapeutics for hormonal and reproductive disorders

    Developing clinical stage small molecule therapeutics to treat hormonal and reproductive system disorders

  2. Slide 2: Forward-Looking Statements

    Forward-Looking Statements This presentation contains forward-looking statements and information regarding the future performance and actions of Repros Therapeutics Inc. (RPRX) that involve risks and uncertainties that could cause actual results and actions to differ materially. These risks include

  3. Slide 3: Repros Strategy

    Repros Strategy Focus on small molecule therapeutics for reproductive system disorders that exhibit significant market potential and that are currently underserved Develop highly differentiable drugs Proellex for the treatment of uterine fibroids and endometriosis Androxal for the treatment of endoc

  4. Slide 4: Proellex

    Reprds Proellex™

  5. Slide 5: Proellex Product Development Timeline

    Proellex Product Development Timeline H1'04 H2'04 H1'05 H2'05 H1'06 H2'06 H1'07 H2'07 H1'08 H2'08 H1'09 H2'09 H1'10 H2'10 Cummulative Spending Euro PHI/II UF PreClin Tox US PH II/III UF Study. US UF Extension Study Carcinogenicity Studies US PH III Anemia Euro Endo Phase II US Endo Phase II US PH II

  6. Slide 6: Proellex Overview

    Proellex Overview New class of selective progesterone receptor modulator (SPRM) No antiglucocorticoid activity Potential indications: uterine fibroids, endometriosis, breast cancer and HRT Potential significant advantages over existing GnRHa therapies No loss of bone mineral density in clinical tria

  7. Slide 7: How Proellex Works

    How Proellex Works Blocks hypothalamus / pituitary axis Shuts down hormonal secretions Long-term side effects including bone loss Selectively blocks progesterone activity Allows tonic hormone secretions Alleviates negative side effects of GnRHa Potential for chronic use GnRHa Proellex Hypothalamus P

  8. Slide 8: Uterine Fibroids

    Uterine Fibroids Benign, monoclonal, hormone sensitive, smooth muscle tumors of the uterus Most common tumor of the female reproductive tract Heavy bleeding / anemia Abdominal pressure / pain / urinary frequency Affect 20-77% of women age 35 - 55 600,000 hysterectomies conducted annually annually an

  9. Slide 9: Uterine Fibroids Large Underserved Market

    Uterine Fibroids Large Underserved Market Conservative Estimate, 15% of women of reproductive age with symptomatic uterine fibroids 174,716,000 women in US, Japan, France, Germany, Italy, Spain, UK of reproductive age Potentially 26,000,000 women with symptomatic uterine fibroids 300,000 women in US

  10. Slide 10: Large Untapped Pharmaceutical Opportunity

    Large Untapped Pharmaceutical Opportunity Assume only the 700,000 women per year requiring surgery would potentially seek a drug treatment Assume the drug would be used for the 10 years between the ages of 39 and 49 to avoid surgery and reach menopause (7,000,000 patients potentially using drug per

  11. Slide 11: Key Symptom Driving Women to Seek Therapy for Uterine Fibroids

    Key Symptom Driving Women to Seek Therapy for Uterine Fibroids Excessive Menstrual Bleeding Spotting Light Moderate Heavy 12.5 0.8 0.4 2.2 0.4 25 1.8 2.2 0.4 0.4 50 3.6 0.4 0.6 0.4 Lupron 8.6 2.4 1.6 2.4 Placebo 13.4 7.6 8.6 2.2 European Pilot Study (n=30) BL Mo 1 Mo 2 Mo 3 Placebo 113.5 91 83 69 Pr

  12. Slide 12: Proellex Produces Significant Clinical Benefit in Uterine Fibroids

    Proellex Produces Significant Clinical Benefit Resulting in Substantially Asymptomatic Uterine Fibroids Symptom Severity Concern Placebo 40.1 61.6 12.5 mg Proellex 17.4 83.6 25 mg Proellex 14.9 86.6 Normal 22.5 84 UFSQOL Uterine Fibroid Symptom Survey p vs placebo < 0.0001 for both doses p vs placeb

  13. Slide 13: Basis for New IND for Pre-Surgical Treatment of Anemia

    Basis for New IND for Proellex for the Pre-Surgical Treatment of Anemia Associated with Uterine Fibroids BL Mo 1 Mo 2 Mo 3 Placebo 10.6 10.6 10.5 10.2 Proellex 12.5 mg 10.2 10.3 12 12.4 Proellex 25 mg 9.9 10.8 11.9 12.1 Median Hemoglobin g/DL 12.5 and 25 mg p < 0.002 vs Pl 1 g increase = ~1 pint of

  14. Slide 14: Proellex Experience to Date Suggests Manageable Side Effect Profile

    Proellex Experience to Date Suggests Manageable Side Effect Profile Most common drug related side effects Amenorrhea: 78.6% (no longer considered a side effect) Hot Flashes: 16.7% With a small data base, differences in low incidence events have to be interpreted with caution No tendency towards bone

  15. Slide 15: Endometriosis

    Definition: the presence of epithelial and stromal endometrial cells outside of the uterine cavity Complaints of infertility or pregnancy loss Pelvic pain/back pain Dyspareunia (pain during sex) Dysmenorrhea (menstrual cycle cramps) Endometriosis 5% of women of reproductive age Estimated that 25 - 4

  16. Slide 16: Endometriosis Large Underserved Market

    Endometriosis Large Underserved Market Estimate, 10% of women of reproductive age with endometriosis 174,716,000 women in US, Japan, France, Germany, Italy, Spain, UK of reproductive age Potentially 17,000,000 women with endometriosis Market for endometriosis drug treatments in 2007 roughly $1.2 bil

  17. Slide 17: Large Untapped Pharmaceutical Opportunity

    Large Untapped Pharmaceutical Opportunity Even though large population of women with endometriosis exists, poor treatment options and poor diagnosis limits the current market for endometriosis Nevertheless $1.2 billion are spent in the major markets If only 10% of the estimated number of women with

  18. Slide 18: Key Symptom Driving Women to Seek Therapy for Endometriosis

    Key Symptom Driving Women to Seek Therapy for Endometriosis Pelvic Abdominal Pain Fewer mean days of pain with 50mg Proellex (higher percentage of pain free days than with Lupron) p< 0.05 Lupron not statistically different than 12.5mg and 25mg Proellex dose % Pain Free Days As Reported thru Month 6

  19. Slide 19: General Concern for Treatment with Progesterone Receptor Modulators

    General Concern for Treatment with Progesterone Receptor Modulators Endometrial Thickening/Hyperplasia? Dosing on Day 5

  20. Slide 20: Proellex Effects on Endometrial Thickness

    Proellex Effects on Endometrial Thickness Month 3 12.5mg 9 25mg 4 Placebo 6 US Phase II/III Study 0 3 6 Lupron 5.3 3.1 3.5 12.5mg 9.8 11.8 20.9 25mg 8.9 12.9 16.6 50mg 11 9.2 14.5 FDA Recommended Thickness Cutoff Statistically Significant Difference In Month 6 Thicknesses

  21. Slide 21: Unopposed Estrogen Effect vs Proellex

    Unopposed estrogen effect vs Proellex Proliferative Disordered Proliferative Benign Endometrial Hyperplasia Estrogen over Time cysts remodeling variable density Mutter et al, 2007 12.5mg Proellex

  22. Slide 22: "Off Drug Interval" Treatment Strategy

    "Off Drug Interval" Treatment Strategy 4 Month Dosing Cycle 4 Month Dosing Cycle 4 Month Dosing Cycle Off Drug Interval to allow for: Menses Refresh the endometrium Experience to date suggests menses returns in 25-35 days Return of symptoms Continue as needed Concept has been accepted by the FDA as

  23. Slide 23: Summary of FDA Meetings Held to Date for Proellex

    Summary of FDA Meetings Held to Date for Proellex FDA willing to consider development of drug for several uterine fibroid indications Preoperative treatment Treatment of perimenopausal women with fibroids Chronic treatment of fibroids to avoid surgery New IND for Anemia to be submitted in Jan'08 Rep

  24. Slide 24: Androxal

    Reprds Androxal

  25. Slide 25: Androxal

    Androxal Trans isomer of clomiphene citrate Cis isomer opposes action and has increased side effect risk Antiestrogen that normalizes pituitary responsiveness in 2^ hypogonadal men Highly statistically significant results in 6 month Phase III study showing restoration of pituitary responsiveness res

  26. Slide 26: Testosterone Market

    Testosterone Market 6/04-6/05 US 461 Rest of World 140 2004 Figures 2003 2004 2005 est. Total Market 399 459 486 Androgel 275 308 326 Androderm 50 57 55 Testim 13 31 43 Testosterone Inj. 31 31 24 A U.S. Phenomenon

  27. Slide 27: Androxal Phase III Trial

    Androxal Phase 3 Trial Enrollment completed in Nov. '06 N = 194 men at 18 US sites Patient testosterone levels < 300 ^g/dl FDA agreement re: safety not efficacy Randomized into 4 arms: 2 doses of Androxal, placebo, and Androgel 6 mo study with efficacy assessment at 3 mo with roll over to 12 mo open

  28. Slide 28: Androxal Type C FDA Meeting Outcome

    Androxal Type C FDA Meeting: Oct. 15,2007 Outcome <300 300-400 400-800 >800 25 mg 17.1 19.5 53.6 9.8 12.5 mg 27.5 25 45 2.5 Androgel 43.2 19.5 34.1 2.4 Placebo 72.5 22.5 0 0 Month 6 Placebo 267.8 Androgel 370.9 12.5 mg Androxal 402.9 25 mg Androxal 508.7 P vs Androgel = 0.009 FDA made the following

  29. Slide 29: Androxal Regulatory Strategy

    Androxal Regulatory Strategy Conduct Phase IIb study in men with AIHH and Metabolic Syndrome Conduct Phase IIb study in hypogonadal men of reproductive age showing improvement or maintenance of fertility/sperm status No primary Quality of Life endpoints

  30. Slide 30: Impact of Hypogonadism on Insulin Sensitivity and Metabolic Syndrome

    Impact of Hypogonadism on Insulin Sensitivity and Metabolic Syndrome T<280 T>280 East 4.3 7.4 American Heart Association definition of Metabolic Syndrome Elevated waist circumference, ^ 40" Triglycerides, ^ 150 mg/dl Reduced HDL, < 40 mg/dl Elevated Blood Pressure, ^ 130/85 Elevated Fasting Glucose,

  31. Slide 31: Change in Serum Glucose

    Change in Serum Glucose Subset of Men BMI>26, Glucose >99 (+50% patients studied) 0 1 2 3 Androxal Pooled 0 -15 -16 -23 No significant change in Placebo or Androgel arms Significant mean change in Androxal arm p<0.01 0 1 2 3

  32. Slide 32: Metabolic Syndrome Clinical Strategy

    Metabolic Syndrome Clinical Strategy Submit white paper to FDA FDA to determine if IND to be moved to endocrine division Commence Phase IIb study in academic setting to elucidate Androxal effects on metabolic syndrome as soon as practical Submit protocol for Phase III study once Phase IIb is complet

  33. Slide 33: Impact of Androxal on Male Fertility

    Impact of Androxal on Male Fertility Baseline 6 Months Androgel 5.42 1.1 12.5 mg Androxal 7.02 9.1 25 mg Androxal 6.4 11.8 Comparison of Means p=0.011 Comparison of Median p=0.0045 32% of men in study under age of 50 Exogenous testosterone suppresses pituitary secretion of FSH FSH required for stimu

  34. Slide 34: Fertility Clinical Strategy

    Fertility Clinical Strategy Submit white paper to FDA Commence Phase IIb study in academic setting to elucidate Androxal effects on fertility Submit protocol for Phase III study once Phase IIb is complete

  35. Slide 35: Androxal Product Development Timeline

    Androxal Product Development Timeline H1'04 H2'04 H1'05 H2'05 H1'06 H2'06 H1'07 H2'07 H1'08 H2'08 H1'09 H2'09 H1'10 H2'10 Cummulative Spending US PHI/II PreClin Tox US PH III Safety Study. US Extension Study Carcinogenicity Studies US PH Ib Fertility US PH IIb metabolism Phase III Studies End of PII

  36. Slide 36: Repros Fundamentals

    Repros Fundamentals Shares Outstanding 12,774,904 (all common, no warrants) 2005 Cash Burn $7,391,000 2006 Cash Burn $14,195,000 (no debt) Burn 2007 ~$14,500,000 Unaudited Cash on 1/6/08 : approximately $25.0million

  37. Slide 37: Repros Ownership

    Repros Ownership Filing on 10-27-06 Total Reporting Shares: 5,993,082 HBK Management LLC 943,400 ProMed Management LLC 843,485 Great Point Partners LLC 721,100 Xmark Opportunity Partners LLC 698,739 Efficacy Capital Ltd 672,528 UBS Securities LLC 628,801 Quogue 605,754 Caxton Associates LLC 177,505

  38. Slide 38: Date Close Volume 10/24/2007 0.075796 10/23/2007 0.2111 10/22/2007 0.0761 10/19/2007 0.099 10/18/2007 0.1058 10/17/2007

    Date Close Volume 10/24/2007 0.075796 10/23/2007 0.2111 10/22/2007 0.0761 10/19/2007 0.099 10/18/2007 0.1058 10/17/2007 0.2012 10/16/2007 0.5684 10/15/2007 0.0367 10/12/2007 0.061 10/11/2007 0.1115 10/10/2007 0.0286 10/9/2007 0.0544 10/8/2007 0.0259 10/5/2007 0.0911 10/4/2007 0.0907 10/3/2007 0.1284

  39. Slide 39: Recent and Upcoming Milestones & Goals

    Recent and Upcoming Milestones & Goals ? 4Q06 Report interim U.S. Phase 3 Androxal results ? 4Q06 Report interim results from Proellex Phase 1/2 endometriosis trial ? 4Q06 Report interim results from Proellex Phase 2/3 fibroid trial ? 1Q07 Raise $33 million in public offering ? 2Q07 Report top-line

  40. Slide 40: Thank you

    Reprds Thank you

Repros Therapeutics — Investor Presentation (January 2008) on 6ix